Instruction for use: Talcid

Active substance Hydrotalcite

ATX Code A02AD04 Hydrotalcite

Pharmacological group

Antacids

Nosological classification (ICD-10)

K21 Gastroesophageal reflux

Biliary reflux esophagitis, gastrocardiac syndrome, Gastroesophageal reflux disease, Gastro-oesophageal reflux disease, Non-erosive reflux disease, syndrome gastrocardiac, Remhelda syndrome, Erosive reflux esophagitis, Ulcerative reflux esophagitis

K25 Gastric ulcer

Helicobacter pylori, Pain syndrome in gastric ulcer, Pain syndrome in gastric ulcer and duodenal ulcer, Inflammation of the gastric mucosa, Inflammation of the gastrointestinal mucosa, Benign gastric ulcer, The disease of the stomach and duodenum, asotsiirovannoe with Helicobacter pylori, Aggravation gastroduodenita on the background of peptic ulcer, Exacerbation of peptic ulcer, The aggravation of gastric ulcer, The organic gastrointestinal disease, Peptic ulcer of the stomach and duodenum, Postoperative gastric ulcer, Recurrent ulcers, Symptomatic gastric ulcers, Chronic inflammatory disease of the upper gastrointestinal tract, associated with Helicobacter pylori, Helicobacter pylori eradication, Erosive and ulcerative lesions of the stomach, Erosive lesions of the stomach, The erosion of the gastric mucosa, Peptic ulcer disease, Stomach ulcer, Gastric lesion, Ulcerative lesions of the stomach, Symptomatic ulcers of the stomach and duodenum

K26 Duodenal Ulcer

Pain with duodenal ulcer, Pain syndrome in gastric ulcer and duodenal ulcer, The disease of the stomach and duodenum, asotsiirovannoe with Helicobacter pylori, Exacerbation of peptic ulcer, The worsening of duodenal ulcer, Peptic ulcer of the stomach and duodenum, Relapse of duodenal ulcers, Symptomatic ulcers of the stomach and duodenum, Helicobacter pylori eradication, Erosive and ulcerative lesions of the duodenum, Erosive-ulcerative lesions of duodenal ulcers associated with Helicobacter pylori, Erosive lesions of the duodenum, Duodenal ulcer, Ulcerative lesions of the duodenum]

K29 Gastritis and duodenitis

Aggravation gastroduodenita on the background of peptic ulcer, duodenitis

K30 Dyspepsia

Fermentation dyspepsia, Hyperacid indigestion, Putrefactive indigestion, Dyspepsia, Dyspepsia, Dyspepsia of nervous origin, Dyspepsia in pregnant women, Dyspepsia fermentation, Dyspepsia putrefactive, Dyspepsia medication, Dyspepsia due to diseases of the digestive system, Dyspepsia due to impaired motility of the gastrointestinal tract, Dyspepsia due to unusual food or overeating, Dyspeptic phenomena during pregnancy, Dyspeptic Syndrome, Gastric indigestion, Delayed emptying of the stomach, Delayed digestion, Idiopathic indigestion, Acid dyspepsia, Disturbance of the upper GI tract motility, Indigestion, Nervous indigestion, Non-ulcer dyspepsia, The feeling of heaviness in the stomach after eating, Postprandial functional dyspepsia, The processes of fermentation in the intestine, Stomach upset, Gastrointestinal disorders, Digestive disorders, Disorders from the digestive tract, Stomach upset, Indigestion disorder, Indigestion in infants, Symptoms of dyspepsia, The syndrome of putrefactive dyspepsia, Syndrome of putrefactive dyspepsia in infants, Syndrome of insufficiency of digestion, Syndrome of nonulcer dyspepsia, Toxic indigestion, Functional dyspepsia, Functional indigestion, Chronic indigestion, Chronic episodes of dyspepsia, Essential dyspepsia, Dyspeptic disorder

Composition and form of release

Tablets chewing 1 tab.

hydrotalcite 500 mg

auxiliary substances: mannitol; corn starch; magnesium stearate; sodium saccharinate; flavoring mint; banana flavor

in a blister of 10 pcs .; in a cardboard bundle of 2 or 5 blisters.

pharmachologic effect

Pharmacological action - antacid, gastroprotective.

Dosing and Administration

Inside, chewed and, if desired, washed down with water.

Acute and chronic gastritis, reflux esophagitis - 500-1000 mg (1-2 tablets) 1-2 hours after meals and before bedtime, and also if necessary.

Peptic ulcer of the stomach and duodenum - 1000 mg (2 tablets) 3-4 times a day after meals and at bedtime. Treatment should be continued for 4 weeks after the symptoms completely disappear.

Heartburn and other gastrointestinal symptoms associated with increased acidity of gastric contents - 500-1000 mg (1-2 tablets) if necessary.

The maximum daily dose of hydrotalcite should not exceed 6000 mg (12 tablets).

Storage conditions

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after the expiry date printed on the package.